Because few data are available on cytogenetic and molecular findings in high-risk CLL, we perform an extensive genetic characterization of 101 CLL with unmutated IGHV and/or 11q22 deletion and/or TP53 disruption. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.